Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRT-089Q01
- Development stage
- Preclinical
- Lead developer
- Sichuan Prite Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
PRT-089Q01 is an investigational humanized biparatopic monoclonal antibody targeting interleukin-33 (IL-33). Developed by Sichuan Purity Pharmaceutical (a subsidiary of Chengdu Brilliant Pharmaceuticals), PRT-089Q01 is designed to compete with the epitopes of both tozorakimab and itepekimab, binding human IL-33 with high affinity. By potently inhibiting the generation of oxidized IL-33 (IL-33ox) and blocking IL-33/ST2 signaling, the antibody suppresses both Th2 and non-Th2 inflammatory pathways and reduces mucin production. PRT-089Q01 is currently in preclinical development for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.
02
Targets
IL1RL1 (Interleukin 1 receptor-like 1 protein)IL33 (IL-33)
Beyond the preview
Go deeper on PRT-089Q01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRT-089Q01.